Testing Vitamin D Supplementation in Early Multiple Sclerosis

Disease activity was lower in patients with clinically isolated syndrome who received vitamin D treatment versus placebo.

Several studies of vitamin D supplementation in multiple sclerosis (MS) have not demonstrated benefit on disease activity but left open the possibility of a benefit on MRI (e.g., NEJM JW Neurol 2024 Jan 30 and Brain 2024; 147:1206). Investigators conducted this multicenter randomized trial in patients diagnosed with clinically isolated syndrome within the previous 90 days, based on not fitting 2010 McDonald diagnostic criteria. Of these participants, 89% would have met the 2017 McDonald criteria for MS. Participants received 100,000 IU of cholecalciferol (156 participants) or placebo (147 participants) orally every 2 weeks for up to 24 months.

The median baseline vitamin D level was 45 nmol/L; 22% of patients had vitamin D deficiency. During…

Reviewing Author

Robert T. Naismith, MD

Disclosures

Consultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Robert T. Naismith, MD

Disclosures

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Testing Vitamin D Supplementation in Early Multiple Sclerosis

Topics

Reviewing Author